RayKnowChina Research Map
Shortlist

JinanShandong First Medical University

Shandong Provincial Hospital

山东省立医院

Listed for 28 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shandong Provincial Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌29 papers led2 open trials led
  2. Hepatocellular carcinoma肝细胞癌76 papers led
  3. Stomach cancer胃癌60 papers led
  4. Hepatoblastoma肝母细胞瘤3 papers led
  5. Osteosarcoma骨肉瘤7 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤5 papers led
  7. Neuroblastoma神经母细胞瘤3 papers led
  8. Ewing sarcoma尤文肉瘤0 papers led
  9. Multiple myeloma多发性骨髓瘤6 papers led
  10. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  11. Aplastic anaemia再生障碍性贫血4 papers led
  12. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  13. Fanconi anaemia范可尼贫血3 papers led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  15. Myasthenia gravis重症肌无力4 papers led
  16. Wilson disease肝豆状核变性(Wilson 病)2 papers led
  17. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎8 papers led
  18. Takayasu arteritis大动脉炎1 paper led
  19. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  20. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  21. Fabry disease法布雷病0 papers led
  22. Pompe disease庞贝病1 paper led
  23. Behçet disease白塞病2 papers led
  24. IgA nephropathyIgA 肾病4 papers led
  25. Osteogenesis imperfecta成骨不全症6 papers led
  26. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  27. Hirschsprung disease先天性巨结肠3 papers led
  28. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led

Not listed for: Nasopharyngeal carcinoma, Retinoblastoma, Chordoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, IgG4-related disease, Moyamoya disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 29 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
29
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 5520232024: 111120242025: 882025

6 hospitals in Jinan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Neoadjuvant QL1706 Therapy for ESCC
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06908382

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Provincial HospitalJinan

  2. Recruiting
    Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT07549100

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Provincial HospitalJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AINeoadjuvant & combined treatment
Departments in papersGastroenterology / hepatologyRadiation oncologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led29
  1. Overexpression of YAP confers radioresistance to esophageal cancer by altering the tumor microenvironment.2025Environmental toxicology
  2. Inhibition of esophageal squamous cell carcinoma progression by MIR210HG and activation of the P53 signaling pathway to promote apoptosis and autophagy.2025European journal of medical researchFree full text
  3. Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.2025Frontiers in immunologyFree full text
  4. SLC25A1 promotes lymph node metastasis of esophageal squamous cell carcinoma by regulating lipid metabolism.2025International journal of oncologyFree full text
  5. Deciphering the generation of heterogeneity in esophageal squamous cell carcinoma metastasis via single-cell multiomics analysis.2025Journal of translational medicineFree full text
  6. SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.2025Nature communicationsFree full text
  7. m6A reader IGF2BP2 mediates paclitaxel resistance in esophageal squamous cell carcinoma via FOXM1 mRNA stabilization.2025Oncology reportsFree full text
  8. HOXA5 Derives the Malignant Progression and Cisplatin Resistance of Esophageal Squamous Cell Carcinoma by Regulating USP18-Mediated IFI27 Deubiquitination.2025Thoracic cancerFree full text
  9. LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression.2024Applied biochemistry and biotechnology
  10. MUC1 promotes lymph node metastasis in esophageal squamous cell carcinoma by downregulating DNAJB6 expression.2024Environmental toxicology
  11. MiR-92a-2-5p suppresses esophageal squamous cell carcinoma cell proliferation and invasion by targeting PRDX2.2024Experimental cell research
  12. VBP1 promotes tumor proliferation as a part of the hypoxia-related signature in esophageal squamous cell carcinoma.2024Human cellFree full text
  13. T cell-related circRNA pairs to predict prognosis of patients with esophageal squamous cell carcinoma.2024International immunopharmacology
  14. The m6A reader IGF2BP2 promotes ESCC progression by stabilizing HDGF mRNA.2024Journal of cancer research and therapeutics
  15. Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms.2024Journal of microbiology and biotechnologyFree full text
  16. Construction of a Novel Mitochondria-Associated Gene Model for Assessing ESCC Immune Microenvironment and Predicting Survival.2024Journal of microbiology and biotechnologyFree full text
  17. Exosomes loaded with the anti-cancer molecule mir-1-3p inhibit intrapulmonary colonization and growth of human esophageal squamous carcinoma cells.2024Journal of translational medicineFree full text
  18. CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.2024Journal of translational medicineFree full text
  19. NUPR1 induces autophagy and promotes the progression of Esophageal squamous cell carcinoma via the MAPK-mTOR pathway.2024Pathology, research and practice
  20. The Function of lncRNA LINC00997 as a Diagnostic Marker in the Progression of Esophageal Squamous Cell Carcinoma.2023Annals of clinical and laboratory science
  21. RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.2023Archives of biochemistry and biophysics
  22. CUL4B enhances the malignant phenotype of esophageal squamous cell carcinoma by suppressing TGFBR3 expression.2023Biochemical and biophysical research communications
  23. Single-cell mapping of N6-methyladenosine in esophageal squamous cell carcinoma and exploration of the risk model for immune infiltration.2023Frontiers in endocrinologyFree full text
  24. A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.2023Journal of cancer research and clinical oncologyFree full text
  25. Hypoxia-inducible factor-2α promotes EMT in esophageal squamous cell carcinoma through the Notch pathway.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  26. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.2022Thoracic cancerFree full text
  27. Downregulation of fibulin-4 inhibits autophagy and promotes the sensitivity of esophageal squamous cell carcinoma cells to apatinib by activating the Akt-mTOR signaling pathway.2022Thoracic cancerFree full text
  28. Knockdown of DEAD-box 51 inhibits tumor growth of esophageal squamous cell carcinoma via the PI3K/AKT pathway.2022World journal of gastroenterologyFree full text
  29. EPB41L5 promotes EMT through the ERK/p38 MAPK signaling pathway in esophageal squamous cell carcinoma.2021Pathology, research and practice
All its trials on ClinicalTrials.gov, any status2
  1. Neoadjuvant QL1706 Therapy for ESCCRecruitingNCT06908382Lead sponsorPhase 2Start 2025-04
  2. Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCCRecruitingNCT07549100Lead sponsorStart 2023-05
More papers found outside PubMed (not counted)17
  1. Study on the effect of molecular regulation on oxaliplatin resistance and macrophage polarization in esophageal squamous cell carcinoma based on the multiomics bioinformatic analysis and experimental verification2025Letters in Drug Design & Discoveryarticle
  2. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technologyarticle
  3. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncologyarticle
  4. Abstract 5208: Dynamic changes in circulating tumor DNA and T cell receptor repertoire predict disease progression in patients with unresectable esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  5. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  6. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  8. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  9. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  10. Construction of a survival model for Esophageal Squamous Carcinoma and prediction of potential treatment with herbal medicine2023Research Squarepreprint
  11. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncologyconference-abstract
  12. The Role of CT-Based Radiomics Nomogram in Differential Diagnosis of Immune Checkpoint Inhibitor-Related Pneumonitis from Radiation Pneumonitis for Patients with ESCC2023International Journal of Radiation Oncology*Biology*Physicsarticle
  13. YAP1-TEAD4-DKK1 is an effective target for inhibiting radiation resistance in esophageal squamous carcinoma and activation of the pathway may be related to poor prognosis of patients2023Research Squarepreprint
  14. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  15. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figsharedataset
  16. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncologyarticle
  17. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 76 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
76
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 171720212022: 151520222023: 101020232024: 141420242025: 19192025

6 hospitals in Jinan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Surgery & liver transplant
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led76
  1. Predictive model development and validation of functional liver imaging score for prognosis of patients with hepatocellular carcinoma after surgical resection: a multicenter study.2026La Radiologia medica
  2. Nomogram to Predict Tumor Remnant of Small Hepatocellular Carcinoma after Microwave Ablation.2025Academic radiology
  3. Artificial intelligence-assisted platform performs high detection ability of hepatocellular carcinoma in CT images: an external clinical validation study.2025BMC cancerFree full text
  4. The E3 ubiquitin ligase TRIM56 promotes aggregation and activation of Src protein through Lys63-linked polyubiquitination in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  5. MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion, proliferation, and epithelial-mesenchymal transition in hepatocellular carcinoma.2025Clinical and experimental medicineFree full text
  6. Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.2025Clinical epigeneticsFree full text
  7. Adrenal crisis occurring after the application of immune checkpoint inhibitors in a hepatitis B - related hepatocellular carcinoma patient: case report and literature review.2025Frontiers in immunologyFree full text
  8. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma in patients with decompensated cirrhosis.2025HPB : the official journal of the International Hepato Pancreato Biliary Association
  9. Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control.2025Immunology
  10. Quality and Reliability of Transarterial Chemoembolization Videos on TikTok and Bilibili: Cross-Sectional Content Analysis Study.2025JMIR formative researchFree full text
  11. Establishment and Validation of Diagnostic Model of Microvascular Invasion in Solitary Hepatocellular Carcinoma.2025Journal of investigative surgery : the official journal of the Academy of Surgical Research
  12. Mechanism of METTL14 regulates HBV-HCC malignant progression by mediating m6A modification of FOXP3 and thus transcriptional activation of ALDOB.2025Journal of molecular histology
  13. Single-cell RNA sequencing reveals a B cell-related immunosuppressive landscape and a potential suppressor in hepatocellular carcinoma.2025Journal of translational medicineFree full text
  14. Microwave Ablation Versus Surgical Resection for Small (≤3 cm) Hepatocellular Carcinoma in Older Patients: A Propensity Score Matching Analysis.2025Korean journal of radiologyFree full text
  15. Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway.2025Oncology researchFree full text
  16. RBBP6-induced destabilization of FOXP3 promotes glucose metabolism and malignant progression of HBV-related hepatocellular carcinoma.2025Pathology, research and practice
  17. The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells.2025Pharmacological research
  18. Nanoparticle conjugation of ginsenoside Rh2 enhanced antitumor efficacy on hepatocellular carcinoma.2025Scientific reportsFree full text
  19. Comprehensive bioinformatics analysis of MEX3 family genes in hepatocellular carcinoma.2025Scientific reportsFree full text
  20. Rapid and portable detection of hepatocellular carcinoma marker alpha-fetoprotein using a droplet evaporation-based biosensor.2025Talanta
  21. A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma.2024Applied biochemistry and biotechnology
  22. Treatment and prognosis study of spontaneous rupture hemorrhage in hepatocellular carcinoma: Recommendations for adding the A1 stage to the BCLC staging system.2024Cancer medicineFree full text
  23. Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.2024Clinical and molecular hepatologyFree full text
  24. Microwave ablation versus laparoscopic resection for hepatocellular carcinoma in patients with clinically significant portal hypertension: a propensity score-matched study of postoperative liver decompensation.2024European radiology
  25. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.2024European radiology
  26. Attenuation of pro-tumorigenic senescent secretory phenotype by StN, a novel derivative of stevioside, potentiates its inhibitory activity on hepatocellular carcinoma.2024Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  27. Investigation on the mechanisms of scorpion venom in hepatocellular carcinoma model mice via untargeted metabolomics profiling.2024International immunopharmacology
  28. Nanotechnology for the Diagnosis and Treatment of Liver Cancer.2024International journal of nanomedicineFree full text
  29. Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance.2024Journal of cancer research and clinical oncologyFree full text
  30. Prognostic Signature Constructed of Seven Ferroptosis-Related lncRNAs Predicts the Prognosis of HBV-Related HCC.2024Journal of gastrointestinal cancer
  31. CT-based radiomics nomogram to predict proliferative hepatocellular carcinoma and explore the tumor microenvironment.2024Journal of translational medicineFree full text
  32. Expression of interleukin-8 and integrin β3 predicts prognosis of patients with hepatocellular carcinoma after hepatectomy.2024MedicineFree full text
  33. Mitochondrial ribosomal protein L12 potentiates hepatocellular carcinoma by regulating mitochondrial biogenesis and metabolic reprogramming.2024Metabolism: clinical and experimental
  34. TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation.2024Molecular cancer research : MCR
  35. From NAFLD to HCC: Advances in noninvasive diagnosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  36. Silencing of RAB42 down-regulated PD-L1 expression to inhibit the immune escape of hepatocellular carcinoma cells through inhibiting the E2F signaling pathway.2023Cellular signalling
  37. Microwave ablation versus radiofrequency ablation as bridge therapy in potentially transplantable patients with single HCC ≤ 3 cm: A propensity score-matched study.2023European journal of radiology
  38. Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score-matched study of long-term therapeutic outcomes.2023European radiology
  39. Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma.2023Gene
  40. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.2023Human & experimental toxicology
  41. Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.2023Journal of cancer research and therapeutics
  42. Multifaceted roles of aerobic glycolysis and oxidative phosphorylation in hepatocellular carcinoma.2023PeerJFree full text
  43. Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma.2023Scientific reportsFree full text
  44. Exosome-mediated transfer of circRNA563 promoting hepatocellular carcinoma by targeting the microRNA148a-3p/metal-regulatory transcription factor-1 pathway.2023World journal of gastroenterologyFree full text
  45. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.2022Asia-Pacific journal of clinical oncologyFree full text
  46. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.2022BMC cancerFree full text
  47. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.2022BMJ openFree full text
  48. An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments.2022BioMed research internationalFree full text
  49. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway.2022BioengineeredFree full text
  50. EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli.2022Cell death & diseaseFree full text
  51. Intrahepatic Splenosis Mimicking Hepatocellular Carcinoma.2022Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  52. Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions.2022European journal of nuclear medicine and molecular imagingFree full text
  53. Quantitative parameters obtained from gadobenate dimeglumine-enhanced MRI at the hepatobiliary phase can predict post-hepatectomy liver failure and overall survival in patients with hepatocellular carcinoma.2022European journal of radiology
  54. Single-direction diffusion-weighted imaging may be a simple complementary sequence for evaluating fetal corpus callosum.2022European radiology
  55. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients.2022European radiology
  56. Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.2022European radiology
  57. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  58. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.2022Journal for immunotherapy of cancerFree full text
  59. Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2022Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  60. CircRNA hsa_circ_0110102 inhibited macrophage activation and hepatocellular carcinoma progression via miR-580-5p/PPARα/CCL2 pathway.2021AgingFree full text
  61. Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2021Annals of surgical oncology
  62. ASO Author Reflections: Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2021Annals of surgical oncology
  63. MKL1 regulates hepatocellular carcinoma cell proliferation, migration and apoptosis via the COMPASS complex and NF-κB signaling.2021BMC cancerFree full text
  64. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.2021BioMed research internationalFree full text
  65. COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC.2021BioMed research internationalFree full text
  66. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.2021BioengineeredFree full text
  67. A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma.2021BioengineeredFree full text
  68. A prediction model of major complications after radiofrequency ablation for recurrent hepatocellular carcinoma patients.2021European journal of radiology
  69. Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  70. MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1.2021Human cell
  71. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  72. A nomogram to predict microvascular invasion in early hepatocellular carcinoma.2021Journal of cancer research and therapeutics
  73. Role of Matrix Metallopeptidase 12 in the Development of Hepatocellular Carcinoma.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  74. Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC.2021Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  75. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram.2021Scientific reportsFree full text
  76. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.2021The Journal of infectious diseases
Chinese-language papers (not in the count)1
  1. [Research progress on the involvement of exosome-mediated intercellular communication in the remodeling and the regulation of invasion and metastasis in the hepatocellular tumor microenvironment].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational StudyActive, not recruitingNCT06096896Lead sponsorStart 2023-08
  2. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  3. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 60 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
60
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 101020212022: 121220222023: 101020232024: 6620242025: 18182025

7 hospitals in Jinan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  2. Recruiting
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06730373

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo

  3. Not yet recruiting
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07828899

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryImaging & AI
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led60
  1. ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer.2026EpigenomicsFree full text
  2. Metabolic reprogramming as a key regulator in Helicobacter pylori-infected gastric cancer.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  3. Neutrophil-Mediated Mechanisms and Therapeutic Reversibility of Gastric Intestinal Metaplasia.2026Journal of gastroenterology and hepatology
  4. Simple Postoperative Markers for Early Identification of Low-Risk Patients After Gastric or Colorectal Cancer Surgery: A Retrospective Cohort Study.2026The American surgeon
  5. Nanoparticle-Mediated CXCL12-CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. A Novel Liver Metastasis Score for Patients Undergoing Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: A Multi-institutional Study.2025Annals of surgical oncology
  7. A risk prediction model for gastric cancer based on endoscopic atrophy classification.2025BMC cancerFree full text
  8. Global, regional, and national burden of gastric cancer attributable to smoking and a high-sodium diet from 1990 to 2021: a global burden of disease study 2021.2025BMC gastroenterologyFree full text
  9. Differentiating the differentiation degree of gastric cancer based on MRI radiomics.2025BMC medical imagingFree full text
  10. Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis.2025Canadian journal of gastroenterology & hepatologyFree full text
  11. A novel 5'tRNA-derived fragment tRF-Tyr inhibits tumor progression by targeting hnRNPD in gastric cancer.2025Cell communication and signaling : CCSFree full text
  12. ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer.2025Cell death & diseaseFree full text
  13. MFGE8 promotes gastric cancer progression by activating the IL-6/JAK/STAT3 signaling.2025Cellular signalling
  14. Defining gastric cancer ecology: the crucial roles of TREM2+ macrophages and fibroblasts in tumor microenvironments.2025Communications biologyFree full text
  15. A nomogram for predicting the risk of liver metastasis in non-functional neuroendocrine neoplasms: A population-based study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  16. Nomogram based on CT imaging and clinical data to predict the efficacy of PD-1 inhibitors combined with chemotherapy in advanced gastric cancer.2025Frontiers in immunologyFree full text
  17. MAZ-mediated LAMA5 transcription activation promotes gastric cancer progression through the STAT3 signaling.2025Functional & integrative genomicsFree full text
  18. Hsa_circ_0006837 suppresses gastric cancer cell proliferation, migration, and invasion via the modulation of miR-424-5p.2025HereditasFree full text
  19. ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer.2025Journal of experimental & clinical cancer research : CRFree full text
  20. Integration of scRNA-seq and ST-seq identifies hyperproliferative RRM2+ cells features and therapeutic targets in gastric cancer.2025Journal of translational medicineFree full text
  21. Prognostic value of neutrophil-lymphocyte ratio in gastroenteropancreatic neuroendocrine neoplasm: a systematic review and meta-analysis.2025PeerJFree full text
  22. Quercetin induces immunogenic cell death against gastric cancer by targeting NR3C1.2025Toxicon : official journal of the International Society on Toxinology
  23. Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer.2024Cell reports
  24. A predictive and prognostic model for metastasis risk and prognostic factors in gastrointestinal signet ring cell carcinoma.2024European journal of medical researchFree full text
  25. Safety and effectiveness of totally laparoscopic total gastrectomy vs laparoscopic-assisted total gastrectomy: a meta-analysis.2024International journal of surgery (London, England)Free full text
  26. Wogonin suppresses proliferation, invasion and migration in gastric cancer cells via targeting the JAK-STAT3 pathway.2024Scientific reportsFree full text
  27. Recurrent Hypoglycemia After Total Gastrectomy: A Case Report and Literature Analysis.2024The American journal of case reportsFree full text
  28. Tumor microenvironment characteristics association with clinical outcome in patients with resected intestinal-type gastric cancer.2024The oncologistFree full text
  29. Correlations between DKI and DWI with Ki-67 in gastric adenocarcinoma.2023Acta radiologica (Stockholm, Sweden : 1987)
  30. TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression.2023BMC cancerFree full text
  31. Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.2023BMC medicineFree full text
  32. Targeting Hippo pathway: A novel strategy for Helicobacter pylori-induced gastric cancer treatment.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: A large-scale study integrating bulk a2023Computers in biology and medicine
  34. CT-based radiomics nomogram for differentiating gastric hepatoid adenocarcinoma from gastric adenocarcinoma: a multicentre study.2023Expert review of gastroenterology & hepatology
  35. Potential Effects of FGFR4 in the Helicobacter pylori-Induced Inflammatory Carcinoma Transformation.2023Gastroenterology
  36. Immunotherapy Efficacy-related Risk Classifier Differentiate Prognostic Characteristics of Gastric Cancer-A Large-scale Retrospective Study.2023Journal of immunotherapy (Hagerstown, Md. : 1997)
  37. A case of endocervical adenocarcinoma of the gastric type that was repeatedly misdiagnosed: A case report and literature review.2023MedicineFree full text
  38. Case report: Gastric adenosquamous carcinoma with EBV-positive component of squamous cell carcinoma mixed with gastric carcinoma with lymphoid stroma: A novel case report and literature review.2023Pathology oncology research : PORFree full text
  39. High Expression of UPK3A Promotes the Progression of Gastric Cancer Cells by Inactivating p53 Pathway.2022Analytical cellular pathology (Amsterdam)Free full text
  40. Long-term outcomes of additional surgery after noncurative endoscopic resection in patients with early gastric cancer: A meta-analysis.2022Asian journal of surgery
  41. LncRNA RPSAP52 promotes cell proliferation and inhibits cell apoptosis via modulating miR-665/STAT3 in gastric cancer.2022BioengineeredFree full text
  42. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.2022Cell death & diseaseFree full text
  43. A novel 3'tRNA-derived fragment tRF-Val promotes proliferation and inhibits apoptosis by targeting EEF1A1 in gastric cancer.2022Cell death & diseaseFree full text
  44. Effect of visceral adipose tissue on the accuracy of preoperative T-staging of gastric cancer.2022European journal of radiology
  45. Impact of preceding noncurative endoscopic submucosal dissection on patients with early gastric cancer who undergo subsequent surgery: a meta-analysis.2022Expert review of gastroenterology & hepatology
  46. Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.2022International journal of clinical practiceFree full text
  47. hsa-miR-875-5p inhibits tumorigenesis and suppresses TGF-β signalling by targeting USF2 in gastric cancer.2022Journal of translational medicineFree full text
  48. Role of transcribed ultraconserved regions in gastric cancer and therapeutic perspectives.2022World journal of gastroenterologyFree full text
  49. LncRNA cancer susceptibility 20 regulates the metastasis of human gastric cancer cells via the miR-143-5p/MEMO1 molecular axis.2022World journal of gastroenterologyFree full text
  50. Overall Survival Advantage of Omentum Preservation Over Omentectomy for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.2022World journal of surgery
  51. KK-LC-1 may be an effective prognostic biomarker for gastric cancer.2021BMC cancerFree full text
  52. Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis.2021BMJ openFree full text
  53. Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma.2021Cancer medicineFree full text
  54. A new candidate oncogenic lncRNA derived from pseudogene WFDC21P promotes tumor progression in gastric cancer.2021Cell death & diseaseFree full text
  55. The flavonoid Astragalin shows anti-tumor activity and inhibits PI3K/AKT signaling in gastric cancer.2021Chemical biology & drug design
  56. miR-885-5p Inhibits Invasion and Metastasis in Gastric Cancer by Targeting Malic Enzyme 1.2021DNA and cell biology
  57. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.2021Expert review of gastroenterology & hepatology
  58. Sesquiterpenoid bilobalide inhibits gastric carcinoma cell growth and induces apoptosis both in vitro and in vivo models.2021Journal of biochemical and molecular toxicology
  59. TNFAIP8 regulates gastric cancer growth via mTOR-Akt-ULK1 pathway and autophagy signals.2021Journal of cellular and molecular medicineFree full text
  60. The role and application of small extracellular vesicles in gastric cancer.2021Molecular cancerFree full text
Chinese-language papers (not in the count)1
  1. [Clinicopathological features and research advances of fundic gland type neoplasms].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status14
  1. Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort StudyStatus unknownNCT05592925Lead sponsorStart 2018-01
  2. Application of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients.Status unknownNCT06260150Lead (inferred)N/AStart 2023-04
  3. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  4. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric CancerNot yet recruitingNCT07828899Study siteN/AStart 2026-10
  5. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Study sitePhase 2Start 2024-10
  6. Postoperative Adjuvant Therapy for Stage II-III Gastric CancerActive, not recruitingNCT06609759Study siteStart 2024-01
  7. Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerActive, not recruitingNCT06157216Study siteN/AStart 2023-10
  8. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Study sitePhase 2Start 2023-02
  9. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Study sitePhase 2Start 2023-03
  10. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  11. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  12. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  13. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  14. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric CarcinomaCompletedNCT01364376Study siteN/AStart 2011-06

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

4 hospitals in Jinan for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 0020232024: 0020242025: 112025

18 hospitals in Jinan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Over half of these papers are lab or animal studies.

Papers it led7
  1. miR-1343-3p, mediated by LncRNA ASMTL-AS1, induces ferroptosis in osteosarcoma progression by targeting TYRO3.2025Gene
  2. Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.2022BMC musculoskeletal disorders
  3. CRISPR/Cas9-mediated overexpression of long non-coding RNA SRY-box transcription factor 21 antisense divergent transcript 1 regulates the proliferation of osteosarcoma by increasing the expression of mechanistic target of rapamycin kinase a2022Bioengineered
  4. Identification of Key Genes and miRNAs Affecting Osteosarcoma Based on Bioinformatics.2022Disease markers
  5. The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells.2021Journal of applied biomedicine
  6. Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells.2021Journal of cellular and molecular medicine
  7. Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells.2021Materials science & engineering. C, Materials for biological applications
Earlier papers (2016–2020)13
  1. CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217.2020European review for medical and pharmacological sciences
  3. MicroRNA-29c-3p inhibits osteosarcoma cell proliferation through targeting PIK3R3.2020European review for medical and pharmacological sciences
  4. Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies.2019BMC cancer
  5. LncRNA KCNQ1OT1 acting as a ceRNA for miR-4458 enhances osteosarcoma progression by regulating CCND2 expression.2019In vitro cellular & developmental biology. Animal
  6. miR-522 stimulates TGF-β/Smad signaling pathway and promotes osteosarcoma tumorigenesis by targeting PPM1A.2019Journal of cellular biochemistry
  7. Selenocysteine inhibits human osteosarcoma cells growth through triggering mitochondrial dysfunction and ROS-mediated p53 phosphorylation.2018Cell biology international
  8. MiR-485-5p inhibits metastasis and proliferation of osteosarcoma by targeting CX3CL1.2018European review for medical and pharmacological sciences
  9. Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors: A meta-analysis of 23 studies.2018Medicine
  10. The prognostic value of PCNA expression in patients with osteosarcoma: A meta-analysis of 16 studies.2017Medicine
  11. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.2016Drug delivery
  12. Propofol suppresses invasion and induces apoptosis of osteosarcoma cell in vitro via downregulation of TGF-β1 expression.2016European review for medical and pharmacological sciences
  13. Meteorin-Like Shows Unique Expression Pattern in Bone and Its Overexpression Inhibits Osteoblast Differentiation.2016PloS one

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 5 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 0020232024: 1120242025: 002025

4 hospitals in Jinan for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led5
  1. Development of a multi-phase CT-based radiomics model to differentiate heterotopic pancreas from gastrointestinal stromal tumor.2024BMC medical imaging
  2. Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection.2022World journal of surgical oncology
  3. Succinate dehydrogenase deficient gastrointestinal stromal tumor in a three month old boy with a fatal clinical course: a case report and review of literature.2021Diagnostic pathology
  4. Association between R1 resection and oncological outcome in resectable gastrointestinal stromal tumors without tumor rupture: A systematic review and meta-analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  5. Clinicopathological characteristics and longterm survival of patients with synchronous multiple primary gastrointestinal stromal tumors: A propensity score matching analysis.2021World journal of gastroenterology
Earlier papers (2016–2020)4
  1. miR-4510 acts as a tumor suppressor in gastrointestinal stromal tumor by targeting APOC2.2020Journal of cellular physiology
  2. Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).2019BMC cancer
  3. Mir-22-3p Enhances the Chemosensitivity of Gastrointestinal Stromal Tumor Cell Lines to Cisplatin through PTEN/PI3K/Akt Pathway.2018Iranian journal of allergy, asthma, and immunology
  4. A gastrointestinal stromal tumor with acute bleeding: Management and nursing.2018Medicine
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

8 hospitals in Jinan for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Jinan for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 222025

7 hospitals in Jinan for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    Phase
    Phase 4
    Started
    2023-10
    Registry
    NCT06057402

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan

  3. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  4. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantDiagnosis, MRD & riskDrug combinations
Papers it led6
  1. Multiple myeloma in a man with breast cancer: A case report and literature review.2025MedicineFree full text
  2. The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).2025Technology in cancer research & treatmentFree full text
  3. Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study.2024Hematology (Amsterdam, Netherlands)
  4. An MRI-based radiomics nomogram for differentiating spinal metastases from multiple myeloma.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  5. Role of ncRNA in multiple myeloma.2022Biomarkers in medicine
  6. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.2021Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
All its trials on ClinicalTrials.gov, any status7
  1. RDD Versus VDD in Newly Diagnosed Patients With Multiple MyelomaStatus unknownNCT03908138Lead sponsorPhase 4Start 2019-03
  2. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Study sitePhase 4Start 2023-10
  5. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  6. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  7. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

2 hospitals in Jinan for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 4 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.0%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 002025

6 hospitals in Jinan for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesClonal evolution & PNHChildren
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Jinan for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 3 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 4.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

2 hospitals in Jinan for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

3 hospitals in Jinan for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging
Departments in papersRadiology / nuclear medicineNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 002025

4 hospitals in Jinan for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesBiologic & complement drugsAntibodies & diagnosisThymus & thymectomy
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

1 hospital in Jinan for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Brain & movement symptomsTreatment (chelation, zinc)
Departments in papersRheumatology & immunologyNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 8 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 3.0%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 0020242025: 442025

5 hospitals in Jinan for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led8
  1. Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis.2025Frontiers in immunology
  2. Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review.2025Frontiers in immunology
  3. Low-dose rituximab for the treatment of anti-NMDAR encephalitis in children: a case series study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Effectiveness of Anti-CD20 B cells depleting therapy versus conventional treatment in severe Anti-N-methyl-d-aspartate receptor encephalitis: A real-world multi-center prospective cohort study.2025Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  5. Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China.2023Frontiers in immunology
  6. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.2021Journal of neuroimmunology
  7. Lipid profiles and their potential inflammatory effects in anti-N-methyl-D-aspartate receptor encephalitis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. High serum creatinine is associated with reduction of psychiatric symptoms in female patients with anti-NMDAR encephalitis.2021Neuroscience letters
Earlier papers (2016–2020)4
  1. The differential expression and potential roles of circular RNAs in children with anti-NMDA receptor encephalitis.2020Journal of neuroimmunology
  2. Clinical features of adult anti-N-methyl-d-aspartate receptor encephalitis after Japanese encephalitis.2020Journal of the neurological sciences
  3. The short-term efficacy of combined treatments targeting B cell and plasma cell in severe and refractory Anti-N-methyl-D-aspartate receptor encephalitis: Two case reports.2019CNS neuroscience & therapeutics
  4. Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour.2017Journal of the neurological sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Jinan for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

8 hospitals in Jinan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Jinan for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Jinan for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)1
  1. [Screening for Fabry disease in patients with kidney disease].2025Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status2
  1. A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseaseCompletedNCT04974749Study sitePhase 3Start 2022-05
  2. Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467Study siteStart 2021-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Jinan for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

2 hospitals in Jinan for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 0020242025: 002025

9 hospitals in Jinan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 6 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 6.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 222025

2 hospitals in Jinan for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

6 hospitals in Jinan for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 3 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

3 hospitals in Jinan for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Jinan for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山东省立医院

Shandong Provincial Hospital

济南

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Shandong Provincial Hospital Affiliated to Shandong University; Shandong Provincial Hospital of Traditional Chinese Medicine; Shandong Provincial Hospital Affiliated; Shandong Provincial Hospital Affiliated Shandong University; Shandong Provincial Hospital affiliated to Cheeloo College of Medicine; Cancer Center of Shandong Provincial Hospital; Shandong Provincial Hospital affiliated to; Shandong Provincial Hospital Heze Branch

Suggest a correctionDownload the data